Lawyer opposes Allergan’s bid for interlocutory appeal in FCA suit

Allergan should not be permitted to immediately appeal against a recent ruling which requires it to face allegations that it monopolised the pricing of dementia drugs, according to a New York-based patent attorney.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

$5.4bn medtech leader fails to bury a rival's patent

19 January 2026 An Israeli medical device company’s lawsuit claims Edwards knowingly infringed its heart-valve patent, raising new risks as the giant pursues growth beyond its core market.

Americas

ITC to probe Oura Ring after Samsung retaliates, seeking import ban

15 January 2026 The wearable tech fight continues as Samsung seeks to block US sales of the Finnish brand's product after being sued over its Galaxy Ring.

Americas

Speciality pharma firm stumbles on bid to enforce Belbuca ruling

15 January 2026 A court has blocked the patent owner's latest attempt to stop a generic rival as it weighs the right way to challenge a new product.